Low Float Profile (NYSE American: MAIA) Oozes Breakout Catalyst Potential (Strong Targets)

Hopefully you were around last week, because even though it may have been cold outside, I heated things up with a fiery hot breakout idea.

*Sponsored Low Float Profile (NYSE American: MAIA) Oozes Breakout Catalyst Potential (Strong Targets) January 13th Greetings, Friend! Hopefully you were around last week, because even though it may have been cold outside, I heated things up with a fiery hot breakout idea. Late Wednesday evening, I highlighted a Nasdaq biopharma profile that was closed out in after-hours at $1.1882. By Friday morning, it had climbed to a pre-market peak of $2.26, delivering an impressive surge of approximately 90% before the market officially opened. However, the action didn’t stop there. Throughout the day, the low float idea experienced multiple double-digit swings (approx.), making for a highly volatile close to the week. But that was then. This is now. At this moment, at least two analysts are painting a rosy picture of an undervalued profile suggesting as much as 400+% potential upside each from this past Friday's closing valuation. On top of that, a couple December press releases may have flown below Wall Street's radar as they highlight a company on an attention-worthy path towards creating much needed cancer treatment options. And based on a low float of fewer than 20Mn shares, volatility could be a major factor for this profile on a daily basis. Consider this breakout idea for your watchlist: MAIA Biotechnology, Inc. (NYSE American: MAIA). MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. Find Key Company Details Here: MAIA Website. MAIA Presentation. These Explosive Potential Catalysts Could Generate Breakout Buzz For (NYSE American: MAIA) #1. MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas Directly from the article: "THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including pediatric high-grade glioma, which is among the most treatment-resistant cancers in children. THIO is shown to activate the immune system while evading tumor immunosuppression, a novel therapeutic approach for this devastating childhood disease," said MAIA Chairman and Chief Executive Officer Vlad Vitoc, M.D. "We are proud to receive the FDA’s Rare Pediatric Disease designation for THIO, which significantly bolsters our plans for continuing research in the PDHGG indication." #2. Major analyst targets suggest serious upside potential (triple-digit!). Noble Capital Markets - $14.00 Target - (Potential upside of 500+% from Friday's close) Key Report Details: Conclusion. Based on the results to date, we look forward to the interim data update and preliminary top-line results from the THIO-001 trial. We are reiterating our Outperform rating and $14 price target. Additionally, in 2024, Diamond Equity Research reiterated a target of $11.25. From Friday's close, that target provides a potential upside over 400%! #3. MAIA has a relatively low float (volatility potential may be explosive). Sporting a float of roughly 19.54Mn shares, according to Yahoo Finance, volatility potential could pop up in a flash. Volatility could be part of the reason why MAIA was able to jump a $1.00+ from a mid-November low to an early December high. #4. MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer From the article: "THIO is showing a survival benefit for patients with advanced NSCLC. As our follow-up continues, we have noted that three of the earliest patients enrolled are approaching 17-month survival. We’re on track to achieve our survival goals in third-line therapy," said Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA. "THIO’s outperformance to date supports our thesis that our telomere targeting agent could become a treatment option for people suffering from advanced NSCLC." ----- Coverage is officially initiated on MAIA Biotechnology, Inc. (NYSE American: MAIA). I'll be in touch with updates when necessary. Talk again soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, a single member limited liability company. Data is provided from third-party sources and MarketPulseToday is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 12/16/2024 and ending on 12/17/2024 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”) to disseminate information about (MAIA:US) via digital communications. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 01/12/2025 and ending on 01/13/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”) to disseminate information about (MAIA:US) via digital communications. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/maia/ A member of Thousand Sun Media LLC is also A member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 01/12/2025 and ending on 01/13/2025 to publicly disseminate information about (MAIA:US) via digital communications. To date, including under the previously described agreement, TD Media LLC has been paid three hundred and thirty-four thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own st-ock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither TD Media LLC or its member owns shares of (MAIA:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/maia/

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice